
    
      In total the study aims to enroll approximately 36 patients who will receive almonertinib in
      combination with chemotherapy in the main trial. The study involves a Screening Period,
      Treatment Period, and Follow up Period. Whilst receiving study medication, it is expected
      patients will attend, on average, approximately 15 visits over the first 12 months and then
      approximately 4 visits per year afterwards. Each visit will last about 2 to 6 hours depending
      on the arrangement of medical assessments by the study centre.
    
  